Alimera Sciences

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Alimera Sciences excels in Q1 2024, eyes revenue growth and market expansion

Alimera Sciences' Q1 2024 performance reflects robust revenue growth, profitability improvements, and strategic initiatives to drive product awareness and clinical advancements.
While facing challenges in margin stabilization and cost management, the company is well-positioned to capitalize on opportunities like indication expansion and sales optimization.
Overall, Alimera Sciences' strong financial performance, focus on innovation, and market expansion efforts position it for continued growth and success in the ophthalmic pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alimera Sciences is a pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. The company is passionate about protecting the retina and developing innovative treatments to preserve vision.

Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?

ANI Pharma

PRINCETON, N.J. & ATLANTA--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patie.

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

ATLANTA--(BUSINESS WIRE)--Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced that it has filed a lawsuit in the Delaware Court of Chancery (the “Court”) to compel ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) to fulfill its contractual obligation to close the transaction contemplated by the companies' previo.

Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences, Inc. (NasdaqGM: ALIM) to ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP). Under the terms of the proposed transaction, shareholders of Alimera will receive $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon th.

ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM

Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.44 per share a year ago.

Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. (“ANI”).

Alimera Sciences Reports Second Quarter 2024 Results

New York, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.

ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.

NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc . ( N asdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.

Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.

Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.

Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher

MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders

Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.

Why Is Alimera Sciences (ALIM) Stock Up 77% Today?

MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.

ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals

Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million.  ANI shares are roughly flat at writing.

Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 is fair to Alimera shareholders. Halper Sadeh encourages Alimera shareholders to click here to learn more about t.

ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders

ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) approved, on May 22, 2024 (the “Grant Date”), inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who were not previously employees or who rejoined the Company following a bona fide period of non-employment, as an inducement material to each such new or re-hired employee's employment (collectively, the “Inducement Awards”).

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alimera Sciences, Inc. (NASDAQ:ALIM ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President U.S. Operations Philip Ashman - President, International Operations Conference Call Participants Chase Knickerbocker - Craig-Hallum Yi Chen - H.C. Wainwright & Company Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.

Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript

Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago.

Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Alimera Sciences Reports First Quarter 2024 Results

Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

AerSale Corp

Cadence Bank

ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.

New Strong Sell Stocks for March 13th

Alimera Sciences, Inc. (NASDAQ:ALIM ) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President, U.S. Operations Conference Call Participants Alex Nowak - Craig-Hallum Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.

Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript

Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.

News for Alimera Sciences Stock (ALIM)